Seegene Inc, a top-tier South Korean PCR molecular diagnostics company, just teamed up with Springer Nature, the big-name publisher behind the scientific journal, Nature. Announced on May 16th, this power duo is all set to shake up the world of disease detection.
Both Seegene and Springer Nature share a dream of making the world healthier and more advanced. They’re planning to use their combined superpowers to help scientists everywhere speed up PCR testing for a bunch of different diseases. Usually, PCR diagnostics companies only roll out a few new products each year, but with Springer Nature’s vast network, they’re looking to fund and tech up global scientists to push out way more diagnostic products.
This whole plan builds on their 2023 Open Innovation Program, which was a big hit. They got 281 applications from 47 countries for just 15 projects, making it a super competitive selection. For 2024, they’re switching things up with a more open format, letting scientists pitch any product ideas they have.
Seegene’s CEO, Dr Jong-Yoon Chun, is super hyped about this next level in their partnership with Springer Nature. He’s all about pushing their SG OneSystemTM business forward to help achieve the goal of a disease-free world.
Frank Vrancken Peeters, the CEO of Springer Nature, is also pumped. He thinks Seegene’s mission to make early disease diagnosis accessible to everyone is awesome and believes it’s only doable through team-ups like this. Springer Nature is all in to help build a global squad of experts using Seegene’s tech to speed up the creation of new tests for tons of health conditions.
Both companies are also planning to expand their team-up efforts, promoting potential partners and hosting annual symposiums, starting with a big joint declaration this year. Marc Spenlé, the COO of Springer Nature, has high hopes for the new Open Innovation Program, aiming to create an ecosystem that fast-tracks the development of much-needed new tests.
